RU2018119104A - Пиримидиновые композиции, их сверхчистые композиции и соли, способы их получения, и способы их применения для лечения заболеваний и состояний, опосредованных н4-гистаминовым рецептором (h4) - Google Patents
Пиримидиновые композиции, их сверхчистые композиции и соли, способы их получения, и способы их применения для лечения заболеваний и состояний, опосредованных н4-гистаминовым рецептором (h4) Download PDFInfo
- Publication number
- RU2018119104A RU2018119104A RU2018119104A RU2018119104A RU2018119104A RU 2018119104 A RU2018119104 A RU 2018119104A RU 2018119104 A RU2018119104 A RU 2018119104A RU 2018119104 A RU2018119104 A RU 2018119104A RU 2018119104 A RU2018119104 A RU 2018119104A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- inhibitors
- dosage form
- diseases
- composition according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562246482P | 2015-10-26 | 2015-10-26 | |
| US62/246,482 | 2015-10-26 | ||
| US201662329091P | 2016-04-28 | 2016-04-28 | |
| US62/329,091 | 2016-04-28 | ||
| US201662359066P | 2016-07-06 | 2016-07-06 | |
| US62/359,066 | 2016-07-06 | ||
| PCT/EP2016/075708 WO2017072131A1 (en) | 2015-10-26 | 2016-10-25 | Pyrimidine compositions, ultra-pure compositions and salts thereof, methods of making the same, and methods of using the same for treating histamine h4 receptor (h4) mediated diseases and conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018119104A true RU2018119104A (ru) | 2019-11-28 |
| RU2018119104A3 RU2018119104A3 (https=) | 2020-02-19 |
Family
ID=57200025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018119104A RU2018119104A (ru) | 2015-10-26 | 2016-10-25 | Пиримидиновые композиции, их сверхчистые композиции и соли, способы их получения, и способы их применения для лечения заболеваний и состояний, опосредованных н4-гистаминовым рецептором (h4) |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20170158671A1 (https=) |
| EP (1) | EP3368528A1 (https=) |
| JP (1) | JP2018531288A (https=) |
| KR (1) | KR20180067683A (https=) |
| CN (1) | CN108602801A (https=) |
| AU (2) | AU2016344627B9 (https=) |
| BR (1) | BR112018007765A2 (https=) |
| CA (1) | CA3001636A1 (https=) |
| CL (1) | CL2018001092A1 (https=) |
| CO (1) | CO2018004323A2 (https=) |
| EC (1) | ECSP18038867A (https=) |
| HK (1) | HK1252050A1 (https=) |
| IL (1) | IL258813A (https=) |
| MX (1) | MX2018005140A (https=) |
| PE (1) | PE20181364A1 (https=) |
| PH (1) | PH12018500822A1 (https=) |
| RU (1) | RU2018119104A (https=) |
| SG (1) | SG11201802676QA (https=) |
| TW (1) | TW201729810A (https=) |
| WO (1) | WO2017072131A1 (https=) |
| ZA (1) | ZA201802183B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| RU2020111694A (ru) * | 2017-10-09 | 2021-11-12 | Тева Фармасьютикал Индастриз Лтд. | Новые соли и твердые формы эсциталопрама |
| WO2019118921A1 (en) | 2017-12-14 | 2019-06-20 | Flodesign Sonics, Inc. | Acoustic transducer drive and controller |
| JP2024506384A (ja) | 2021-02-10 | 2024-02-13 | イオリクス セラピューティクス，インコーポレーテッド | ロフルミラストの眼科的送達方法 |
| CA3231766A1 (en) | 2021-09-22 | 2023-03-30 | Elizabeth W. JEFFORDS | Methods of treating ocular inflammatory diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002072548A2 (en) | 2001-03-09 | 2002-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic compounds and their use as histamine h4 ligands. |
| EP1543011B1 (en) | 2002-09-06 | 2006-05-03 | Janssen Pharmaceutica N.V. | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands |
| KR101235116B1 (ko) * | 2005-10-17 | 2013-02-20 | 에스케이케미칼주식회사 | 광학활성 암로디핀 겐티세이트 염의 제조방법 |
| NL2000323C2 (nl) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
| JP2008127359A (ja) * | 2006-11-22 | 2008-06-05 | Kowa Co | アトピー性皮膚炎の予防及び／又は治療剤 |
| EP3378476A1 (en) * | 2012-06-08 | 2018-09-26 | Sensorion | H4 receptor inhibitors for treating tinnitus |
-
2016
- 2016-10-24 TW TW105134313A patent/TW201729810A/zh unknown
- 2016-10-25 EP EP16785505.5A patent/EP3368528A1/en not_active Withdrawn
- 2016-10-25 JP JP2018540217A patent/JP2018531288A/ja active Pending
- 2016-10-25 AU AU2016344627A patent/AU2016344627B9/en not_active Ceased
- 2016-10-25 US US15/333,713 patent/US20170158671A1/en not_active Abandoned
- 2016-10-25 PE PE2018000602A patent/PE20181364A1/es unknown
- 2016-10-25 CA CA3001636A patent/CA3001636A1/en not_active Abandoned
- 2016-10-25 MX MX2018005140A patent/MX2018005140A/es unknown
- 2016-10-25 SG SG11201802676QA patent/SG11201802676QA/en unknown
- 2016-10-25 HK HK18111382.3A patent/HK1252050A1/zh unknown
- 2016-10-25 KR KR1020187014495A patent/KR20180067683A/ko not_active Withdrawn
- 2016-10-25 RU RU2018119104A patent/RU2018119104A/ru not_active Application Discontinuation
- 2016-10-25 WO PCT/EP2016/075708 patent/WO2017072131A1/en not_active Ceased
- 2016-10-25 US US15/770,825 patent/US20190135787A1/en not_active Abandoned
- 2016-10-25 BR BR112018007765A patent/BR112018007765A2/pt not_active Application Discontinuation
- 2016-10-25 CN CN201680076200.2A patent/CN108602801A/zh active Pending
-
2018
- 2018-04-04 ZA ZA2018/02183A patent/ZA201802183B/en unknown
- 2018-04-17 PH PH12018500822A patent/PH12018500822A1/en unknown
- 2018-04-18 IL IL258813A patent/IL258813A/en unknown
- 2018-04-24 CO CONC2018/0004323A patent/CO2018004323A2/es unknown
- 2018-04-25 CL CL2018001092A patent/CL2018001092A1/es unknown
- 2018-05-21 EC ECIEPI201838867A patent/ECSP18038867A/es unknown
-
2020
- 2020-02-06 AU AU2020200840A patent/AU2020200840A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020200840A1 (en) | 2020-02-27 |
| CA3001636A1 (en) | 2017-05-04 |
| CL2018001092A1 (es) | 2018-08-10 |
| BR112018007765A2 (pt) | 2018-10-23 |
| SG11201802676QA (en) | 2018-05-30 |
| AU2016344627B2 (en) | 2019-11-07 |
| HK1252050A1 (zh) | 2019-05-10 |
| ZA201802183B (en) | 2019-02-27 |
| RU2018119104A3 (https=) | 2020-02-19 |
| WO2017072131A1 (en) | 2017-05-04 |
| PE20181364A1 (es) | 2018-08-27 |
| EP3368528A1 (en) | 2018-09-05 |
| KR20180067683A (ko) | 2018-06-20 |
| AU2016344627B9 (en) | 2019-11-28 |
| ECSP18038867A (es) | 2018-05-31 |
| MX2018005140A (es) | 2018-05-07 |
| CO2018004323A2 (es) | 2018-07-19 |
| CN108602801A (zh) | 2018-09-28 |
| AU2016344627A1 (en) | 2018-05-10 |
| JP2018531288A (ja) | 2018-10-25 |
| TW201729810A (zh) | 2017-09-01 |
| IL258813A (en) | 2018-06-28 |
| US20190135787A1 (en) | 2019-05-09 |
| PH12018500822A1 (en) | 2018-10-01 |
| US20170158671A1 (en) | 2017-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018119104A (ru) | Пиримидиновые композиции, их сверхчистые композиции и соли, способы их получения, и способы их применения для лечения заболеваний и состояний, опосредованных н4-гистаминовым рецептором (h4) | |
| CN105664164B (zh) | 使用选择性的bcl-2抑制剂的治疗方法 | |
| EP1755561B1 (en) | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines | |
| CR20210271A (es) | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso | |
| JP2019503365A5 (https=) | ||
| US11278508B2 (en) | Compounded compositions and methods for treating pain | |
| SI2529622T1 (en) | Inhibitors of bruton's tyrosine kinase | |
| JP2018531288A5 (https=) | ||
| JP2005515966A5 (https=) | ||
| US20150202186A1 (en) | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | |
| US20210322438A1 (en) | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis | |
| RS59313B1 (sr) | Orvepitant za lečenje hroničnog kašlja | |
| JP6062705B2 (ja) | 医薬組成物 | |
| US11737975B2 (en) | Compounded compositions and methods for treating pain | |
| WO2005094832A1 (en) | Compositions comprising meloxicam | |
| JP2013237709A (ja) | Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬 | |
| JPH06502166A (ja) | イブプロフェン−抗ヒスタミン薬の組み合わせ | |
| WO2021074284A1 (fr) | Utilisation de nictotinamide mononucléotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes | |
| JP2005263743A (ja) | ロイコトリエン産生抑制作用を有する医薬組成物 | |
| JP2010195716A (ja) | 点鼻睡眠導入剤 | |
| TW202415369A (zh) | 醫藥組成物 | |
| Polski et al. | Review on analgesic effect of co-administrated ibuprofen and caffeine | |
| JP2010241834A (ja) | 医薬組成物 | |
| JP4344532B2 (ja) | 鼻炎用組成物 | |
| JP2022016650A (ja) | ロキソプロフェン又はその塩及びビタミンｂ１２類を含有する経口用医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210209 |